VIVUS, Inc. (VVUS) Pops as Larger Qsymia Retail Presence Expected Soon
Tweet
Share
E-mail
Get Alerts VVUS Hot Sheet
Price: $0.47 --0%
Financial Fact:
Total operating expenses: 14.2M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total operating expenses: 14.2M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) shares are ripping following Q1 results reported earlier. However, he move might be tied to more than just the numbers.
Ahead of the bell Wednesday, VIVUS reported a loss of 53 cents on revs of $4.1 million, both missing consensus views. The loss was wider than 20 cents per share reported in the same period last year.
On the company's post-earnings conference call, CEO Leland Wilson commented that VIVUS is beginning discussions with large pharmaceutical companies in order to "significantly expand commercialization efforts for Qsymia." Wilson is looking to bring Qsymia into retail pharmacies by the middle of July.
Holding back strong Qsymia sales was insurers continues reluctance to reimburse on the drug, the first diet pill approved for use in the U.S. in over 13 years. Lack of retail presence was another factor in the results.
Results from VIVUS come as competitor Arena Pharmaceuticals (Nasdaq: ARNA)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
Ahead of the bell Wednesday, VIVUS reported a loss of 53 cents on revs of $4.1 million, both missing consensus views. The loss was wider than 20 cents per share reported in the same period last year.
On the company's post-earnings conference call, CEO Leland Wilson commented that VIVUS is beginning discussions with large pharmaceutical companies in order to "significantly expand commercialization efforts for Qsymia." Wilson is looking to bring Qsymia into retail pharmacies by the middle of July.
Holding back strong Qsymia sales was insurers continues reluctance to reimburse on the drug, the first diet pill approved for use in the U.S. in over 13 years. Lack of retail presence was another factor in the results.
Results from VIVUS come as competitor Arena Pharmaceuticals (Nasdaq: ARNA)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- BMO starts chip stocks coverage: Here are its preferred picks
- Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
Create E-mail Alert Related Categories
Conference Calls, FDA, Insiders' Blog, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
